Full-service CRO, biotech-focused. Highest growth in the sector. Small/mid-biotech client mix gives maximum leverage to funding recovery — and maximum downside to funding freeze.
Research snapshot · Not reviewed
MEDPMedpace
Full-service CRO, biotech-focused
Open MEDP in Robinhood ↗Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$15.92BSnapshot value
Biotech funding recovery accelerating; small/mid-biotech trial demand; specialized in complex therapeutic areas (oncology, rare disease).
Highest funding-cycle beta in the sector — first hit on biotech funding freeze; elevated cancellations; trial demand has not fully recovered; premium valuation.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🔴 Caution · ins-$39.3M · 13F 15+/10- · short↑0.41
Snapshot · Not reviewed